| Literature DB >> 21073692 |
Youping Deng1, David R Johnson, Xin Guan, Choo Y Ang, Junmei Ai, Edward J Perkins.
Abstract
BACKGROUND: Evolution of toxicity testing is predicated upon using in vitro cell based systems to rapidly screen and predict how a chemical might cause toxicity to an organ in vivo. However, the degree to which we can extend in vitro results to in vivo activity and possible mechanisms of action remains to be fully addressed.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21073692 PMCID: PMC2998496 DOI: 10.1186/1752-0509-4-153
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Figure 1Commonly significantly regulated transcripts by TNT . For the in vivo experiment, rats were exposed to TNT at various doses: 0 (control), 4.8, 48, 96 or 192 mg/kg for 24 h or 48 h. Subsequently rats were sacrificed and RNAs were isolated for microarray hybridization using a Rat Agilent whole genome array. For in vitro experiments, primary cultured rat liver cells were treated with TNT at 10 mg/l or vehicle control, and RNAs were isolated for microarray experiments using the same type of Agilent array as the in vivo experiment. Differentiated transcripts were analyzed as described in the Materials and Methods. The commonly regulated transcripts are shown in the intersection part of the Venn diagram.
Figure 2Hierarchical clustering of experimental conditions. Experimental conditions were based on averaging samples with the same treatments or controls of both in vitro and in vivo experiments. Total 12 experimental conditions including 10 in vivo and 2 in vitro were put together for a Two-Way hierarchical clustering. 341 common transcripts (horizontal axis) were used for clustering across all the conditions (vertical axis). A Pearson correlation algorithm was applied to calculate the distances between transcripts or between conditions. The relative level of gene expression is indicated by the color scale at the right side.
Figure 3Comparison of upregulated and downregulated transcripts between . Among 341 commonly regulated transcripts regulated by TNT in vitro and in vivo, commonly upregulated transcripts (A) and downregulated transcripts(B) of these 341 transcripts between in vivo TNT treatment at 199 mg/ml for 24 h and in vitro TNT treatment are shown by the Venn diagram.
Significant functional categories based on genes commonly regulated by TNT in vivo and in vitro
| Category | P-value | Downregulated genes* | Upregulated genes* |
|---|---|---|---|
| Cell Cycle | 5.1E-07-1E-02 | ANGPTL2, LGALS1, CYP26B1, COL1A1, CCND2, CKAP2, CDKN3, KIF20A, CXCL12, ECT2, CCNB1, RARB, PTTG1, LZTS1, TFDP2, BCL2A1, CDC2, INPP5D | MYC, CCNC, DNM1L, NRG2(includesEG:9542), MAPK1, NRG1, TFRC, PPARG, CREG1, RIOK3, NTRK1, DUSP13, ADM |
| Carbohydrate Metabolism | 1.36E-06-1E-02 | GCK, MMP2, INPP5 D, PTTG1, CXCL12, LGALS1 | NQO1, ADM, PLA2G7, UGDH, GCLC, PPP1R3C, NTRK1, PPARG, JMJD7, PLA2G4B, ABCC3, UGT1A6, CPT1A, PARD3, NRG1, H6PD, SLC5A3, MYC |
| Molecular Transport | 1.36E-06-1E-02 | GCK, PTTG1, CXCL12, LGALS1 | MYC, SLC5A3, ABCG5, EIF2S1, GMFB, H6PD, MAPK1, NRG1, PARD3, CPT1A, TFRC, ABCC3, PPARG, AQP8, ABCC4, PPP1R3C, GCLC, ADM, NQO1 |
| Cellular Growth and Proliferation | 1.25E-05-1E-02 | LGALS1, COL1A1, CCND2, KIF20A, CXCL12, CCNB1, RARB, PTTG1, LZTS1, HSD11B2, DLC1, COL1A2, BCL2A1, CDC2, INPP5 D, MMP2 | MYC, DNAJB6, NRG2 (includes EG:9542), CES2 (includes EG:8824), MAFF, CDH4 (includesEG:1002), UGT2B17, MAPK1, NRG1, TRIM35, TFRC, PPARG, CXCL2, ALDH1L1, CREG1, GSTP1, HMGCR, NTRK1, CDA, PHLDA1, PFN2, GRIN2C, ADM, CYP1A1 |
| Cell Death | 3.45E-05-1E-02 | LGALS1, CYP26B1, CCND2, CKAP2, CXCL12, CCNB1, RARB, PTTG1, HSD11B2, DLC1, BCL2A1, CDC2, INPP5 D, MMP2 | MYC, DNAJB6, EIF2S1, DNM1L, NRG2(includes EG:9542), GMFB, HTATIP2, MAPK1, NRG1, TRIM35, TFRC, EPHX1, PPARG, CXCL2, SQSTM1, CYP2F1, GSTP1, GSR, NTRK1, ABCC4, PHLDA1, GCLC, PLA2G7, TXNRD1, NR1I3, GRIN2C, ADM, NQO1, NCF2 |
| DNA Replication, Recombination, and Repair | 1.52E-04-1E-02 | LGALS1, CCND2, CXCL12, ECT2, CCNB1, PTTG1, MMP2 | MYC, NRG2 (includes EG:9542), PDE5A, NRG1, PPARG, RIOK3, GSTP1, GCLC, NR1I3, ADM, AMPD3, NQO1 |
| Lipid Metabolism | 2.6E-04-1E-02 | GCK, INPP5 D, HSD11B2, CXCL12, PNPLA3, LGALS1 | CYP1A1, ADM, PLA2G7, PPP1R3C, UGT2B7, NTRK1, ACOT4, GSTP1, AQP8, PPARG, JMJD7-PLA2G4B, ABCC3, RDH16, CPT1A, MAPK1, H6PD, UGT2B17, CYP3A43, CYP2C18, ABCG5, MYC |
| Cellular Assembly and Organization | 5.88E-04-1E-02 | LGALS1, COL1A1, ECT2, CCNB1, PTTG1, COL1A2, CDC2, KRT20, INPP5D | MYC, DNAJB6, DNM1L, EPB41, NRG1, RIOK3, PFN2, ADM |
| Immune Cell Trafficking | 3.58E-03-1E-02 | COL1A1, CYTIP, CXCL12 | CXCL2 |
| Humoral Immune Response | 5.57E-03-1E-02 | CXCL12, BCL2A1, NPP5D | MYC, NTRK1 |
* Full names of the genes are listed in Additional file 1, Table S 1.
Commonly regulated canonical pathways based on in vivo, in vitro and common gene lists regulated by TNT
| Pathway | -Log(P-value) | -Log(P-value) | -Log(P-value) |
|---|---|---|---|
| Metabolism of Xenobiotics by Cytochrome P450 | 7.26 | 4.77 | 5.82 |
| NRF2-mediated Oxidative Stress Response | 6.17 | 6.05 | 5.31 |
| LPS/IL-1 Mediated Inhibition of RXR Function | 5.66 | 6.29 | 3.48 |
| Glutathione Metabolism | 8.31 | 3.33 | 3.14 |
| Xenobiotic Metabolism Signaling | 5.05 | 5.14 | 4.4 |
| Pentose and Glucuronate Interconversions | 4.63 | 3.67 | 4.37 |
| Aryl Hydrocarbon Receptor Signaling | 3.82 | 3.84 | 3.93 |
| PXR/RXR Activation | 3.28 | 4.34 | 1.84 |
| Pyruvate Metabolism | 4.54 | 2.15 | 1.25 |
| Galactose Metabolism | 4.11 | 1.44 | 1.73 |
| Fructose and Mannose Metabolism | 4.19 | 1.33 | 1.65 |
| Retinol Metabolism | 1.98 | 1.97 | 2.59 |
| Biosynthesis of Steroids | 1.83 | 1.56 | 2.28 |
| Fatty Acid Metabolism | 2.3 | 1.87 | 1.48 |
| Starch and Sucrose Metabolism | 1.11 | 1.48 | 2.24 |
| Androgen and Estrogen Metabolism | 1.31 | 1.34 | 1.74 |
Figure 4Top significantly canonical pathways based on . Three separate gene lists resulted from most significantly regulated gene list in vivo(A), significantly regulated gene list in vitro(B) and commonly regulated gene list between in vivo and in vitro (C) were used to run the pathway analysis. The bigger the -log(p-value) of a pathway is, the more significantly the pathway is regulated. The threshold lines represent a p value with 0.05. Top 15 most significantly regulated pathways for each list are presented.
Figure 5Comparison of significantly canonical pathways based on . Three separate gene lists resulted from most significantly regulated gene list in vivo, significantly regulated gene list in vitro and commonly regulated gene list between in vivo and in vitro were used to run the Ingenuity pathway analysis tool. The overlapped significantly regulated pathways are presented in the Venn diagram. A pathway enrichment p value less than 0.05 was considered as significant.
Top common pathways regulated by TNT in vitro and in vivo
| Canonical Pathways | Common regulated genes* |
|---|---|
| Metabolism of Xenobiotics by Cytochrome P450 | CYP3A43, CYP2F1, GSTP1, CYP1A1, CYP2C18, UGT1A6, UGT2B7, GSTA5, ALDH1L1, UGT2B17, EPHX1 |
| NRF2-mediated Oxidative Stress Response | GSR, AKR7A3, GSTP1, MAPK1, GSTA5, NQO1, GCLC, SQSTM1, DNAJB6, MAFF, TXNRD1, EPHX1 |
| Xenobiotic Metabolism Signaling | GSTP1, CYP1A1, UGT1A6, MAPK1, GSTA5, NQO1, ALDH1L1, GCLC, CES2 (includes EG:8824), UGT2B7, NR1I3, UGT2B17, ABCC3 |
| Aryl Hydrocarbon Receptor Signaling | MYC, GSTP1, CYP1A1, CCND2, MAPK1, GSTA5, NQO1, RARB, ALDH1L1 |
| Pentose and Glucuronate Interconversions | TCAG7.1260, AKR7A3, UGDH, UGT1A6, UGT2B7, UGT2B17 |
| LPS/IL-1 Mediated Inhibition of RXR Function | GSTP1, ABCG5, CPT1A, GSTA5, NR1I3, ALDH1L1, CES2 (includes EG:8824), ABCC3, ABCC4 |
| Glutathione Metabolism | GSR, GSTP1, GSTA5, H6PD, GCLC |
| PXR/RXR Activation | CPT1A, NR1I3, CES2 (includes EG:8824), ABCC3 |
* Full names of the genes are listed in Additional file 1, Table S 1
Figure 6. Both gene networks were built using common genes regulated by TNT in vivo and in vitro. The in vivo gene network (A) was constructed using 200 arrays from rat liver tissues treated with one of 5 compounds TNT, 2,4-DNT, 2,6-DNT, 2A-DNT and 4A-DNT or vehicle controls. The in vitro gene network (B) was modeled using 531 arrays resulted from liver primary cultured cells treated by one of 105 compounds with relative controls. The Context Likelihood of Relatedness (CLR) algorithm was employed to build both gene networks. Yellow highlighted genes are transcription factors. (C) Number of connections of transcription factors in vivo and in vitro gene networks. The number of connections of transcription factors in vivo and in vitro gene networks exhibited in Fig. 6A, B was counted.
Figure 7Conserved sub gene networks between . By comparing in vivo and in vitro gene networks (shown in Fig. 6), conserved subnetworks that had the same connections in the both networks were achieved. Transcription factors are highlighted as yellow.
Figure 8Quantitative real-time RT-PCR (QRT-PCR) verification of microarray gene expression. Both QRT-PCR (A) and microarray (B) results of the gene PTTG1(G) were presented. The experimental design was the same as the microarray experiment. The expression value for a given gene was represented as a log2 ratio of ratio of exposed versus respective control RNA. The correlation of total 13 genes across different conditions (n = 156) between the microarray and RT-PCR data was shown on Fig. 8C. Bars represent the standard errors for the average log2 ratios of biological replicates.